


Fluasterone

Cat. No.:	HY-106328
CAS No.:	112859-71-9
Molecular Formula:	C ₁₉ H ₂₇ FO
Molecular Weight:	290.42
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Fluasterone is a potent G6PD inhibitor with a K _i of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active ^{[1][2][3]} .								
IC₅₀ & Target	Ki: 0.51 μM (G6PD) ^[3]								
In Vivo	<p>Fluasterone (0.2% and 0.3%; in diet for 39 days) shows anti-hyperglycemic effect in diabetic mice^[2].</p> <p>Fluasterone (200 μg/mouse; intradermal injection; once) suppresses the TPA-induced acute inflammatory and epidermal hyperplastic effect^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57BL/KsJ db/db mice, diabetic model^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0.2% and 0.3%</td> </tr> <tr> <td>Administration:</td> <td>In the diet for 39 days</td> </tr> <tr> <td>Result:</td> <td>Markedly reduced plasma glucose levels.</td> </tr> </table>	Animal Model:	Male C57BL/KsJ db/db mice, diabetic model ^[2]	Dosage:	0.2% and 0.3%	Administration:	In the diet for 39 days	Result:	Markedly reduced plasma glucose levels.
Animal Model:	Male C57BL/KsJ db/db mice, diabetic model ^[2]								
Dosage:	0.2% and 0.3%								
Administration:	In the diet for 39 days								
Result:	Markedly reduced plasma glucose levels.								

REFERENCES

- [1]. Schwartz AG, et al. Potential therapeutic use of dehydroepiandrosterone and structural analogs. *Diabetes Technol Ther.* 2001 Summer;3(2):221-4.
- [2]. Pashko LL, et al. Antihyperglycemic effect of dehydroepiandrosterone analogue 16 alpha-fluoro-5-androsten-17-one in diabetic mice. *Diabetes.* 1993 Aug;42(8):1105-8.
- [3]. Schwartz AG, et al. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. *Cancer Lett.* 2001 Jul 10;168(1):7-14.
- [4]. Schwartz AG, et al. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. *Cancer Lett.* 2001 Jul 10;168(1):7-14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA